Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
LACTOSE INDIA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LACTOSE INDIA Mar-23 |
ADCOCK INGRAM Jun-14 |
LACTOSE INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 96 | 316 | - | |
Low | Rs | 39 | 228 | - | |
Sales per share (Unadj.) | Rs | 52.3 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | 1.0 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 4.7 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 32.2 | 73.8 | - | |
Shares outstanding (eoy) | m | 12.59 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 2.9 | 44.8% | |
Avg P/E ratio | x | 70.6 | -11.5 | -615.0% | |
P/CF ratio (eoy) | x | 14.5 | -13.9 | -104.5% | |
Price / Book Value ratio | x | 2.1 | 3.7 | 57.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 854 | 45,919 | 1.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 122 | 2,882 | 4.2% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 658 | 15,870 | 4.1% | |
Other income | Rs m | 7 | 111 | 6.6% | |
Total revenues | Rs m | 665 | 15,982 | 4.2% | |
Gross profit | Rs m | 115 | -2,750 | -4.2% | |
Depreciation | Rs m | 47 | 685 | 6.8% | |
Interest | Rs m | 60 | 430 | 14.0% | |
Profit before tax | Rs m | 15 | -3,754 | -0.4% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3 | 235 | 1.1% | |
Profit after tax | Rs m | 12 | -3,999 | -0.3% | |
Gross profit margin | % | 17.4 | -17.3 | -100.5% | |
Effective tax rate | % | 17.5 | -6.2 | -279.4% | |
Net profit margin | % | 1.8 | -25.2 | -7.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 375 | 11,624 | 3.2% | |
Current liabilities | Rs m | 266 | 6,540 | 4.1% | |
Net working cap to sales | % | 16.6 | 32.0 | 51.9% | |
Current ratio | x | 1.4 | 1.8 | 79.4% | |
Inventory Days | Days | 46 | 111 | 41.1% | |
Debtors Days | Days | 693 | 124 | 559.1% | |
Net fixed assets | Rs m | 643 | 6,775 | 9.5% | |
Share capital | Rs m | 126 | 74 | 170.9% | |
Net worth | Rs m | 406 | 12,457 | 3.3% | |
Long term debt | Rs m | 330 | 4,377 | 7.5% | |
Total assets | Rs m | 1,018 | 23,531 | 4.3% | |
Interest coverage | x | 1.2 | -7.7 | -16.1% | |
Debt to equity ratio | x | 0.8 | 0.4 | 231.8% | |
Sales to assets ratio | x | 0.6 | 0.7 | 95.8% | |
Return on assets | % | 7.1 | -15.2 | -46.9% | |
Return on equity | % | 3.0 | -32.1 | -9.3% | |
Return on capital | % | 10.2 | -19.8 | -51.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 81 | 1,355 | 5.9% | |
From Investments | Rs m | -10 | -416 | 2.4% | |
From Financial Activity | Rs m | -84 | 3,973 | -2.1% | |
Net Cashflow | Rs m | -13 | 4,912 | -0.3% |
Compare LACTOSE INDIA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare LACTOSE INDIA With: INNOVA CAPTAB LTD. COLINZ LABOR ALKEM LABORATORIES EVEREST ORGANICS LINCOLN PHAR
Indian share markets continued the momentum as the session progressed and ended the higher.